GBMTARGET · Targeting Glioblastoma Signalling
FP7 — People (Marie Curie Actions)
- Duration
- 2014-03-01 → 2016-02-29
- EU contribution
- €309,235
- Participants
- 1
- Scheme
- MC-IEF
Lines connect the coordinator with its partners.
Results in brief
Targeting Glioblastoma Signalling
GBMTarget established a computational strategy exploiting polypharmacology to identify drug targets in biological systems implicated in disease. We identified multiple targets in protein networks associated with the disease to thereby enable repositioning of drugs against that disease. The efficacy of the approach was tested by using the platform to identify compounds against gliomas (including glioblastoma multiforme). The novelty of GBMTarget lies in its use of CATH-FunFams, a definition of protein domains developed in the Orengo group to link known and putative drug compounds to biological networks. We have demonstrated that CATH-FunFams are the druggable entities within protein targets and developed a scheme to associate drugs to protein domains. We have modelled the signalling in gliomas as a network, to identify potential targets, and we proposed drugs active on them based on our drug-domain associations. Our computational platform is easily extensible to other cancer types and even other diseases, enabling an efficient and cost-effective strategy for the identification of pharmacological targets and the repurposing of drugs.
Data: CORDIS, © European Union
Project objective
This project will establish a computational strategy which exploits polypharmacology to identify drug targets in biological systems implicated in cancer. The value of our polyphamacology platform will be tested by application to glioblastoma multiforme, a deadly brain cancer. The aim will be to identify multiple targets in protein networks linked to glioblastoma to thereby enable repositioning of drugs against that cancer. The novelty of the work will lie in its use of protein domain structure data to link known and putative drug compounds to biological networks.The project is proposed as an interdisciplinar and intersectoral research: (i) It will be developed on the basis of the domain structure resources and expertise in the host group of Prof. Orengo at University College London (UCL), and the compound-target libraries and drug discovery expertise within the pharmaceutical company GlaxoSmithKline, which will be a seconded host institution; (ii) it will benefit from the expertise in protein-ligand interactions developed in the group of Prof. Janet Thornton and the group of Prof. John Overington at the European Bioinformatics Institute; (iii) the experimental testing of putative drug compounds will be undertaken in collaboration with the group of Dr Matilda Katan-Muller at UCL and the group of Prof David Selwood at UCL.
Original text from CORDIS.
Participants
- UNIVERSITY COLLEGE LONDON · LONDONCoordinatorUnknown Region
Links
Data: CORDIS, © European Union